Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase 1/2 Completed
107 enrolled 24 charts
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Phase 2 Completed
30 enrolled 8 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Phase 2 Completed
37 enrolled 8 charts
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Phase 1/2 Completed
29 enrolled 10 charts
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Phase 1 Completed
23 enrolled 7 charts
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
80 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Phase 1 Completed
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed